Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vismodegib

FDA-approved product (capsule, oral), marketed as Erivedge.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Vismodegib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Basal cell carcinoma
  • Cancer
  • Neoplasm
  • Skin basal cell carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hedgehog pathway inhibitors
FDA pharmacologic class
Hedgehog Pathway Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vismodegib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vismodegib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis

    NCT02648048 · start 2016-01-15

    Registered record
    Registry ID
    NCT02648048
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    Pirfenidone; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-01-15
    Completion
    2016-11-30
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    InterventionPirfenidone; Vismodegib
    PhasePhase 1
    Registry statusCompleted

  • A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors

    NCT02366312 · start 2015-10-27

    Registered record
    Registry ID
    NCT02366312
    Conditions
    Keratocystic Odontogenic Tumor
    Interventions
    vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-10-27
    Completion
    2019-08
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratocystic Odontogenic Tumor
    Interventionvismodegib
    PhasePhase 2
    Registry statusCompleted

  • Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

    NCT02337517 · start 2015-09-08

    Registered record
    Registry ID
    NCT02337517
    Conditions
    Chronic Graft Versus Host Disease
    Interventions
    Laboratory Biomarker Analysis; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-09-08
    Completion
    2018-06-28
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Graft Versus Host Disease
    InterventionLaboratory Biomarker Analysis; Vismodegib
    PhasePhase 2
    Registry statusTerminated

  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    NCT02465060 · start 2015-08-17

    Registered record
    Registry ID
    NCT02465060
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent O
    Interventions
    Adavosertib; Afatinib; Afatinib Dimaleate; Binimetinib; Biopsy Procedure; Biospecimen Collection; Capivasertib; Computed Tomography; Copanlisib; Copanlisib Hydrochloride; Crizotinib; Cytology Specimen Collection Procedure; Dabrafenib; Dabrafenib Mesylate; Dasatinib; Defactinib; Defactinib Hydrochloride; Echocardiography Test; Erdafitinib; Fexagratinib; Ipatasertib; Laboratory Biomarker Analysis; Larotrectinib; Larotrectinib Sulfate; Magnetic Resonance Imaging; Multigated Acquisition Scan; Nivolumab; Osimertinib; Palbociclib; Pertuzumab; PI3K-beta Inhibitor GSK2636771; Radiologic Examination; Radionuclide Imaging; Relatlimab; Sapanisertib; Sunitinib Malate; Taselisib; Trametinib; Trastuzumab; Trastuzumab Emtansine; Ulixertinib; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-08-17
    Completion
    2026-12-31
    Enrolment
    6,452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma +38 more
    InterventionAdavosertib; Afatinib; Afatinib Dimaleate; Binimetinib +38 more
    PhasePhase 2
    Registry statusActive not recruiting

  • VISmodegib for ORbital and Periocular Basal Cell Carcinoma

    NCT02436408 · start 2015-07-15

    Registered record
    Registry ID
    NCT02436408
    Conditions
    Carcinoma, Basal Cell
    Interventions
    Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-07-15
    Completion
    2020-09
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Basal Cell
    InterventionVismodegib
    PhasePhase 4
    Registry statusCompleted

  • Observational Study of Vismodegib (Erivedge) in Patients Treated in Argentina

    NCT02438644 · start 2015-06-30

    Registered record
    Registry ID
    NCT02438644
    Conditions
    Basal Cell Carcinoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-06-30
    Completion
    2017-07-26
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Carcinoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML

    NCT02073838 · start 2015-05

    Registered record
    Registry ID
    NCT02073838
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Ribavirin; Vismodegib; Decitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-05
    Completion
    2022-11
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionRibavirin; Vismodegib; Decitabine
    PhasePhase 2
    Registry statusCompleted

  • A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)

    NCT02371967 · start 2015-04-08

    Registered record
    Registry ID
    NCT02371967
    Conditions
    Basal Cell Carcinoma
    Interventions
    Vismodegib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-04-08
    Completion
    2020-08-19
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Carcinoma
    InterventionVismodegib
    PhaseNot recorded
    Registry statusCompleted

  • Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)

    NCT02667574 · start 2014-11-18

    Registered record
    Registry ID
    NCT02667574
    Conditions
    Basal Cell Carcinoma
    Interventions
    ERIVEDGE
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-11-18
    Completion
    2020-07-15
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Carcinoma
    InterventionERIVEDGE
    PhasePhase 2
    Registry statusCompleted

  • A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

    NCT02168530 · start 2014-10

    Registered record
    Registry ID
    NCT02168530
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    placebo; vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2014-10
    Completion
    2017-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    Interventionplacebo; vismodegib
    PhasePhase 2
    Registry statusWithdrawn

  • A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy

    NCT02115828 · start 2014-04

    Registered record
    Registry ID
    NCT02115828
    Conditions
    Prostate Cancer
    Interventions
    Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2014-04
    Completion
    2016-04
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionVismodegib
    PhaseEarly phase 1
    Registry statusCompleted

  • Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms

    NCT01893892 · start 2014-03

    Registered record
    Registry ID
    NCT01893892
    Conditions
    Musculoskeletal Complications
    Interventions
    levocarnitine; placebo; questionnaire administration
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-03
    Completion
    2017-03-15
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMusculoskeletal Complications
    Interventionlevocarnitine; placebo; questionnaire administration
    PhaseNot applicable
    Registry statusCompleted

  • A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

    NCT01878617 · start 2013-06-23

    Registered record
    Registry ID
    NCT01878617
    Conditions
    Medulloblastoma
    Interventions
    Craniospinal Irradiation with boost to the primary tumor site; Cyclophosphamide; Cisplatin; Vincristine; Vismodegib; Pemetrexed; Gemcitabine; Aerobic Training; Neurocognitive Remediation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2013-06-23
    Completion
    2031-10-13
    Enrolment
    660

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedulloblastoma
    InterventionCraniospinal Irradiation with boost to the primary tumor site; Cyclophosphamide; Cisplatin; Vincristine +5 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma

    NCT01774253 · start 2013-05

    Registered record
    Registry ID
    NCT01774253
    Conditions
    Pontine Glioma
    Interventions
    Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-05
    Completion
    2015-10
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPontine Glioma
    InterventionVismodegib
    PhasePhase 2
    Registry statusTerminated

  • Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma

    NCT01835626 · start 2013-05

    Registered record
    Registry ID
    NCT01835626
    Conditions
    Locally Advanced Basal Cell Carcinoma; Skin Cancer; Cutaneous Malignancy
    Interventions
    Vismodegib; Radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-05
    Completion
    2019-09-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Basal Cell Carcinoma; Skin Cancer; Cutaneous Malignancy
    InterventionVismodegib; Radiation therapy
    PhasePhase 2
    Registry statusCompleted